175 related articles for article (PubMed ID: 32862501)
21. The predictive value of the prognostic staging system in the 8th edition of the American Joint Committee on Cancer for triple-negative breast cancer: a SEER population-based analysis.
Liu YY; Yu TJ; Liu GY
Future Oncol; 2019 Feb; 15(4):391-400. PubMed ID: 30620221
[TBL] [Abstract][Full Text] [Related]
22. Axillary Management of Stage II/III Breast Cancer in Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-Positive) and CALGB 40603 (Triple-Negative).
Ollila DW; Cirrincione CT; Berry DA; Carey LA; Sikov WM; Hudis CA; Winer EP; Golshan M
J Am Coll Surg; 2017 Apr; 224(4):688-694. PubMed ID: 28089784
[TBL] [Abstract][Full Text] [Related]
23. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.
Parthan A; Santos E; Becker L; Small A; Lalla D; Brammer M; Teitelbaum A
J Manag Care Spec Pharm; 2014 May; 20(5):485-93. PubMed ID: 24761820
[TBL] [Abstract][Full Text] [Related]
24. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients Running title: BCS had better prognosis than mastectomy for early TNBC patients.
Wang SE; Sun YD; Zhao SJ; Wei F; Yang G
Math Biosci Eng; 2019 Sep; 17(1):92-104. PubMed ID: 31731341
[No Abstract] [Full Text] [Related]
25. Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype.
Brandão M; Morais S; Lopes-Conceição L; Fontes F; Araújo N; Dias T; Pereira D; Borges M; Pereira S; Lunet N
ESMO Open; 2020 Nov; 5(6):e000984. PubMed ID: 33234552
[TBL] [Abstract][Full Text] [Related]
26. Health system costs for cancer medications and radiation treatment in Ontario for the 4 most common cancers: a retrospective cohort study.
Mittmann N; Liu N; Cheng SY; Seung SJ; Saxena FE; Look Hong NJ; Earle CC; Cheung MC; Leighl NB; Coburn NG; DeAngelis C; Evans WK
CMAJ Open; 2020; 8(1):E191-E198. PubMed ID: 32184283
[TBL] [Abstract][Full Text] [Related]
27. Total Mastectomy or Breast Conservation Therapy? How Radiation Oncologist Accessibility Determines Treatment Choice and Quality: A SEER Data-base Analysis.
Churilla TM; Donnelly PE; Leatherman ER; Adonizio CS; Peters CA
Breast J; 2015; 21(5):473-80. PubMed ID: 26133235
[TBL] [Abstract][Full Text] [Related]
28. Real-life clinical pattern, management, and survival in Thai patients with early-stage or metastatic triple-negative breast cancer.
Srimuninnimit V; Pornpraserthsuk P; Chaiwerawattana A; Kongdan Y; Namkanisorn T; Somwangprasert A; Jatuparisuthi C; Puttawibul P; Vongsaisuwan M; Thongthieang L; Bandidwattanawong C; Tantimongkolsuk C
PLoS One; 2018; 13(12):e0209040. PubMed ID: 30566471
[TBL] [Abstract][Full Text] [Related]
29. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
Tzikas AK; Nemes S; Linderholm BK
Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
[TBL] [Abstract][Full Text] [Related]
30. Impact of metastatic colorectal cancer stage and number of treatment courses on patient health care costs and utilization.
Chastek B; Kulakodlu M; Valluri S; Seal B
Postgrad Med; 2013 Mar; 125(2):73-82. PubMed ID: 23816773
[TBL] [Abstract][Full Text] [Related]
31. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.
Biswas T; Efird JT; Prasad S; James SE; Walker PR; Zagar TM
Clin Breast Cancer; 2016 Jun; 16(3):212-6. PubMed ID: 26988771
[TBL] [Abstract][Full Text] [Related]
32. Cost of managing women presenting with stage IV breast cancer in the United Kingdom.
Remák E; Brazil L
Br J Cancer; 2004 Jul; 91(1):77-83. PubMed ID: 15188011
[TBL] [Abstract][Full Text] [Related]
33. Randomized Phase II Trial of Anthracycline-free and Anthracycline-containing Neoadjuvant Carboplatin Chemotherapy Regimens in Stage I-III Triple-negative Breast Cancer (NeoSTOP).
Sharma P; Kimler BF; O'Dea A; Nye L; Wang YY; Yoder R; Staley JM; Prochaska L; Wagner J; Amin AL; Larson K; Balanoff C; Elia M; Crane G; Madhusudhana S; Hoffmann M; Sheehan M; Rodriguez R; Finke K; Shah R; Satelli D; Shrestha A; Beck L; McKittrick R; Pluenneke R; Raja V; Beeki V; Corum L; Heldstab J; LaFaver S; Prager M; Phadnis M; Mudaranthakam DP; Jensen RA; Godwin AK; Salgado R; Mehta K; Khan Q
Clin Cancer Res; 2021 Feb; 27(4):975-982. PubMed ID: 33208340
[TBL] [Abstract][Full Text] [Related]
34. Treatment Patterns and Associated Health Care Costs Before and After Treatment Initiation Among Pulmonary Arterial Hypertension Patients in the United States.
Burger CD; Ozbay AB; Lazarus HM; Riehle E; Montejano LB; Lenhart G; White RJ
J Manag Care Spec Pharm; 2018 Aug; 24(8):834-842. PubMed ID: 29436260
[TBL] [Abstract][Full Text] [Related]
35. Descriptive study of triple negative breast cancer in Eastern Algeria.
Souad H; Zahia F; Abdelhak L; Karima S; Dalila S; Noureddine A
Pan Afr Med J; 2018; 29():45. PubMed ID: 29875927
[TBL] [Abstract][Full Text] [Related]
36. Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney.
Naher S; Tognela A; Moylan E; Adams DH; Kiely BE
Intern Med J; 2018 May; 48(5):567-572. PubMed ID: 28967175
[TBL] [Abstract][Full Text] [Related]
37. The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States.
Sieluk J; Song Y; Freimark J; Huang M; Haiderali A; Berman R; Wang T; Signorovitch J; Hirshfield KM
Adv Ther; 2022 Feb; 39(2):943-958. PubMed ID: 34918193
[TBL] [Abstract][Full Text] [Related]
38. Treatment patterns, clinical outcomes, health resource utilization, and cost in patients with BRCA-mutated metastatic breast cancer treated in community oncology settings.
Houts AC; Olufade T; Shenolikar R; Walker MS; Schwartzberg LS
Cancer Treat Res Commun; 2019; 19():100121. PubMed ID: 30785027
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics, risk factors, and outcomes in Chilean triple negative breast cancer patients: a real-world study.
Acevedo F; Walbaum B; Medina L; Merino T; Camus M; Puschel K; Ramírez K; Manzor M; Veglia P; Martinez R; Guerra C; Navarro M; Bauerle C; Dominguez F; Sánchez C
Breast Cancer Res Treat; 2023 Jan; 197(2):449-459. PubMed ID: 36414796
[TBL] [Abstract][Full Text] [Related]
40. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
